This content is in French.
ctDNA: promise of precision or reflection of inequality?
24 octobre 2025
By Ana Espino | Published on October 24, 2025 | 3 min readBreast cancer is the most common malignancy among women worldwide. Despite major therapeutic advances, a substantial proportion of patients remain at risk of relapse, particularly those with residual disease after neoadjuvant therapy. Residual disease is a strong prognostic factor for early recurrence, especially in aggressive subtypes such
By Ana Espino | Published on October 24, 2025 | 3 min read
Breast cancer is the most common malignancy among women worldwide. Despite major therapeutic advances, a substantial proportion of patients remain at risk of relapse, particularly those with residual disease after neoadjuvant therapy. Residual disease is a strong prognostic factor for early recurrence, especially in aggressive subtypes such as triple-negative breast cancer (TNBC) and HER2-positive disease. Early detection of residual disease or imminent recurrence is therefore a critical challenge for improving personalized care and overall survival.
Breast cancer is the most common malignancy among women worldwide. Despite major therapeutic advances, a substantial proportion of patients remain at risk of relapse, particularly those with residual disease after neoadjuvant therapy. Residual disease is a strong prognostic factor for early recurrence, especially in aggressive subtypes such as triple-negative breast cancer (TNBC) and HER2-positive disease. Early detection of residual disease or imminent recurrence is therefore a critical challenge for improving personalized care and overall survival.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Aronson, J., et al. (2025). Bridging the gap: ctDNA, genomics, and equity in breast cancer care. NPJ breast cancer, 11(1), 92
View the source
